QLGN News and Press, Qualigen Therapeutics Inc. From 12/15/20

Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology CARLSBAD, Calif. , Dec. 15, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing no...

Penny Stocks to Watch Today Finding the best penny stocks to buy seems simple, but it takes time to identify a clear trend. We saw this week, how quickly these can breakout. We’ve also seen how quickly they can break down. So deciding what type of trading strategy you’...

Immutep (IMMP) +132% after breast cancer trial shows promising survival data.Greenwich LifeSciences (GLSI) +57%.UTStarcom Holdings (UTSI) +50%.Panbela Therapeutics (PBLA) +46%.Leju Holdings (LEJU) +38%.SELLAS Life Sciences (SLS) +36%.ClearOne (CLRO) +35% to expand its footprint in M...

Cancer Stocks Are Surging This Week Cancer penny stocks took off this week thanks to a little help from one of the small caps making headlines. This morning, Greenwich LifeSciences ( GLSI Stock Report ) announced big news on its cancer treatment candidate. A poster presentat...

Qualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief Strategy Officer and Names Sidney Emery, Jr. to its Board CARLSBAD, Calif. , Dec. 8, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developin...

Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials CARLSBAD, Calif. , Dec. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of i...

Qualigen Therapeutics (QLGN): FQ2 GAAP EPS of -$0.41 misses by $0.61.Revenue of $0.84M (-30.0% Y/Y) misses by $0.75M.Press Release For further details see: Qualigen Therapeutics EPS misses by $0.61, misses on revenue

Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results PR Newswire CARLSBAD, Calif., Nov. 13, 2020 CARLSBAD, Calif. , Nov. 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (...

Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials PR Newswire CARLSBAD, Calif., Nov. 5, 2020 CARLSBAD, Calif. , Nov. 5, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced today it has...

Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19 Plans to File IND Application and Initiate Phase 2a Study in First Half of 2021 PR Newswire CARLSBAD, Calif., Oct. 28, 2020 CARL...